Method of diagnosis and treatment: WO 2014/012147 A1

Lead investigator on 3 patents titled “Method of diagnosis": PCT/AU2013/000801 (National phase), PCT/AU2016/050392, PCT/AU2017/050111 (PCT application stage)


Duivenvoorden HM, Spurling A, O’Toole S and Parker BS (2018) Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers, PLOSOne, doi: 10.1371/journal.pone.0201370.

Smedley CJ, Stanley PA, Qazzaz M, Prota AE, Olieric N, Collins H, Eastman H, Barrow A, Lim K, Kam T, Smith B, Duivenvoorden HM, Parker BS, Bradshaw TD, Steinmetz M and Moses J (2018) Sustainable Syntheses of (-)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding Site, Scientific Reports, 8(1): 10617.

Brockwell NK and Parker BS (2018) Tumor inherent interferons: Impact on immune reactivity and immunotherapy, Cytokine, doi: 10.1016/j.cyto.2018.04.006.

Owen KL and Parker BS (2017) Beyond the viscious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis, Mol Immunol., doi: 10.1016/j.molimm.2017.11.023.

Gangoda L, Liem M, Ang CS, Keerthikumar S, Adda C, Parker B and Mathivanan S (2017) Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential, Proteomics, 17(23-24), doi: 10.1002/pmic.201600370.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O’Toole SA and Parker BS (2017) Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion, Journal of Pathology, 243(4): 496-509, doi: 10.1002/path.4990.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden H, Baschuk N, Caramia F, Loi S, Darcy PK Lim E and Parker BS (2017) Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC, Cancer Immunology Research, 5(10): 871-884, doi: 10.1158/2326-6066.CIR-17-0150.

Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG and Cutts SM (2017) Encapsulation of mitoxantrone within cucurbit[8]uril decreases toxicity and enhances survival in a mouse model of cancer, ACS Med Chem Lett., 8(5): 538-542.

Touati N, Tryfonidis K, Caramia F, Bonnefoi H, Cameron D, Slaets L, Parker BS and Loi S (2016) Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumor suppressor in breast cancer, Eur J Cancer, doi: 10.1093/annonc/mdw365.35.

Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, Lobb RJ, Castillo V, Wong KN, Ellis S, Parker BS and Möller A (2016) The biodistribution and immune suppressive effects of breast cancer-derived exosomes, Cancer Res.,76(23): 6816-27.

Edgington-Mitchell LE, Wartmann T, Fleming AK, Gocheva G, van der Linden WA, Withana NP, Verdoes M, Aurelio L, Edgington-Mitchell D, Lieu T, Parker BS, Graham B, Reinheckel T, Furness JB, Joyce JA, Storz P, Halangk W, Bogyo M and Bunnett NW (2016) Legumain is activated in macrophages during pancreatitis, Am J Physiol Gastrointest Liver Physiol., 311(3): G548-60.

Parker BS*, Rautela J and Hertzog P* (2016) Antitumour actions of type I interferons: implications for cancer therapy, Nat Rev Cancer, 16(3): 131-44.

Rautela J, Baschuk N, Slaney C, Jayatilleke K, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A and Parker BS (2015) Loss of host type-I IFN signaling accelerates metastasis and impairs NK cell anti-tumor function in multiple models of breast cancer, Cancer Immunol Res., 3(11): 1207-17.

Wong CS, Chen A, Liu MC, Parker BS and Möller A (2015) Loss of Siah2 does not impact angiogenic potential of murine endothelial cells, Microvasc Res., doi: 10.1016/j.mvr.2015.08.003.

Edgington-Mitchell L, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M and Parker BS (2015) Cysteine cathepsin activity suppresses osteoclatogenesis of myeloid-derived suppressor cells in breast cancer, Oncotarget, 6(29): 27008-22.

Croucher PI, Parker BS, Corcoran N and Rogers MJ (2015) Bone turnover markers and prostate cancer: not just a measure of bone disease? Eur Urol., 68(1): 51-52.

Baschuk N, Rautela J and Parker BS (2015) Bone specific immunity and its impact on metastasis, Bonekey Rep., 4:665, doi: 10.1038/bonekey.2015.32.

Gangoda L, Keerthikumar S, Fonseka P, Edgington LE, Ang CS, Ozcitti C, Bogyo M, Parker BS and Mathivanan S (2015) Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin, Oncotarget, 6(13): 1175-90.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL and Anderson RL (2014) Bone morphogenetic protein 4 inhibits breast cancer metastasis by blocking myeloid derived suppressor cell activity, Cancer Res., 74(18): 5091-102.

Edgington-Mitchell LE and Parker BS (2014) Disparate roles for myeloid-derived suppressor cells in cancer metastasis, Cancer Forum, 38(2): 107-11.

Slaney CY, Rautela J and Parker BS (2013) The emerging role of immune surveillance in dictating metastatic spread in breast cancer, Cancer Res., 73(19): 5852-57.

Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter S, De Weerd N, Roisman LC, Rossjohn J,  Robertson S, Schjenken J, Parker BS, Gargett C, Nguyen HPT, Carr DJ,  Hansbro PM and Hertzog PJ (2013) Interferon epsilon is a novel, innate cytokine that protects the reproductive tract from viral and bacterial infection, Science, 339(6123): 1088-92.

Slaney CY, Möller A, Hertzog PJ and Parker BS (2013) The role of Type I interferons in immunoregulation of breast cancer metastasis to bone, Oncoimmunology, 2(1): e22339.

Sceneay J, Parker BS, Smyth MJ and Möller A (2013) Hypoxia-driven immunosuppression contributes to the premetastatic niche, Oncoimmunology, 2(1): e22355.

*Contributed equally to work.